A Multicenter Randomized Trial Evaluating Posaconazole versus Fluconazole for the Treatment of Oropharyngeal Candidiasis in Subjects with HIV/AIDS | Zendy

José A. Vázquez | Zendy; Daniel J. Skiest | Zendy; Leonardo Nieto | Zendy; R Northland | Zendy; I. Sanne | Zendy; Jagadish Gogate | Zendy; Wayne Greaves | Zendy; Randi Isaacs | Zendy

Open Access

A Multicenter Randomized Trial Evaluating Posaconazole versus Fluconazole for the Treatment of Oropharyngeal Candidiasis in Subjects with HIV/AIDS

Author(s) -

José A. Vázquez,

Daniel J. Skiest,

Leonardo Nieto,

R Northland,

I. Sanne,

Jagadish Gogate,

Wayne Greaves,

Randi Isaacs

Publication year - 2006

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/501457

Subject(s) - posaconazole , fluconazole , medicine , candida glabrata , candida krusei , adverse effect , candida albicans , human immunodeficiency virus (hiv) , mycosis , randomized controlled trial , microbiology and biotechnology , immunology , antifungal , dermatology , itraconazole , biology

Oropharyngeal candidiasis is the most common opportunistic infection among persons infected with human immunodeficiency virus (HIV). Use of some agents is hampered by lack of efficacy, emergence of resistance, adverse events, and need for intravenous administration. Posaconazole is an extended-spectrum triazole with potent in vitro activity against Candida species, including Candida albicans, Candida glabrata, and Candida krusei (including fluconazole-resistant strains).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research